Leadership & Board

For more than 20 years John Kelly has championed the cause of reimagining medical devices to enhance their usability and performance. Before founding Atomo Diagnostics in 2010, John was Chief Operating Officer at ASX listed (now NASDAQ listed) Unilife Corporation, where he led the ‘Unifill’ development team to develop the world’s first glass prefilled drug delivery device with integrated auto retract safety feature. This technology was successfully licensed to Sanofi Aventis. Previously, John led the New Product Implementation Group at ResMed, where he managed the design and commercialisation of the ground-breaking Mirage Swift mask. In addition to his commercial experience, John has an Honours Degree in Mechanical Engineering from the University of Liverpool, a Master’s Degree in Systems Engineering from Queen’s University Belfast, and an Executive MBA from the University of Sydney, where he was awarded the Business School’s inaugural ‘Excellence in Leadership’ scholarship.

Chandra joined Atomo in 2017 as Director of Programs bringing with her more than 25 years of experience within the medical device industry. She has extensive experience in the development of medical devices from conception to commercialisation. Prior to joining Atomo, she served in a variety of leadership roles within ResMed, including supply chain management, global manufacturing, and APAC marketing. Chandra holds a Bachelors Honours degree in Physics and an executive MBA from AGSM.

Dr. Walker is an executive with more than twenty-five years of experience working with life science and diagnostic companies. Employing years in the financial markets as a stock analyst, commercial execution to meet aggressive growth targets, and more than 45 successfully closed mergers, acquisitions and divestitures, she has worked as part of and with management teams, private equity and venture firms to develop the best strategies to build their life science business and to execute on acquisition strategies or sale of the company. Dr. Walker is currently the CEO of Zeta Corporation and has previously served as President, Chief Executive Officer, and Director of Rhinostics, an early-stage spin-out company based on technology initially developed at Harvard University. She has also held senior executive positions at Abcam; Charles River Labs; Qiagen, and Life Technologies, now part of ThermoFisher. Dr. Walker holds a BA in Biology from Swarthmore College and a Ph.D. in Human and Molecular Genetics from Baylor College.

An experienced Non-Executive Director and Chair with over 35 years experience as a senior executive in medical devices & point-of-care diagnostics sectors within various multinational, private and listed biotechnology companies. Currently serves as Non-Executive Director at Workplace Drug Testing Australasia Ltd and as a Committee Member at Animal Ethics Committee QUT. Previously served as Non-Executive Director & Chair at eWaste Connection Ltd, Board Member at Prostate Cancer Foundation of Australia (Qld), a Fellow of the Australian Institute of Company Directors and holds degrees in Science and Marketing.

Mr May has held various Director roles across international corporations including Hoechst Germany, Microgenics Corporation USA, Fisher Scientific and Thermo Fisher Scientific. With extensive experience across public and private pathology laboratories, as well as sales and management roles in the IVD supply sector, he has built a strong track record in business leadership and strategic growth. Mr May is a member of the Australasian Association for Clinical Biochemistry and Laboratory Medicine and holds a bachelor’s degree in science.